CD274 and metastatic neoplasm: Within metastatic CCRCC, plasma and tissue expression of PD-1 and PD-L1 were analyzed according to the IMDC risk classification and also according to the Morphology, Attenuation, Size and Structure (MASS) response criteria in patients receiving systemic therapy for metastatic disease.